Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Israel / NCT06990217
Starting soon Phase 4

Comparing High Versus Low Dose of Oxytocin, in Gravida Women With BMI 30 and Above Which Are Undergoing Induction of Labor

NCT06990217 · tracked via the Priya Life Science Israel tracker
Sponsor
HaEmek Medical Center, Israel
Phase
Phase 4
Started
2025-06
Last updated
2025-05-25

Condition(s) studied

Induction of LaborAugmentation of Labor

Investigational drug(s) / intervention(s)

Oxytocin Grindeks 10 IU/ml- solution for injection →

Oxytocin Grindeks 10 IU/ml- solution for injection: our study is aims to compare two oxytocin regimens - low VS high dose among obese women who need induction or augmentation of labor

Study summary

The goal of this clinical trial is to compare between higher and lower dose of oxytocin to induce delivery in obese women. Researches will compare between low and high doses of oxytocin. the study group will use high dose of oxytocin (20 units in 1000 ml) versus the control group which will use low dose of oxytocin (10 units of oxytocin in 1000 ml)

Eligibility

Sex
FEMALE
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Women at term (37-42 weeks), requiring the use of oxytocin for induction of labor or for augmentation of labor. * BMI 30 and above * Viable singleton pregnancies * Cephalic presentation. * No contraindication for vaginal delivery Exclusion Criteria: * Women with previous cesarean delivery * Multiple pregnancy * Multiple fetal malformations * IUFD

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Haemek Medical Center Afula Israel

More HaEmek Medical Center, Israel trials in Israel

Explorative Study for Treating Persistent Developmental Stuttering With Ramipril Active, not recruiting
Induction of Labor - Comparison Propess With Prostaglandin E2 Vaginal Gel and Balloon Catheter Recruiting
Virtual Reality for Pain and Anxiety During HyFoSy Starting soon
Preliminary Effectiveness of Individual and Group MDMA-assisted Therapy for Israeli Veterans With PTSD and Moral Injury. Recruiting

Other trials for the same condition

Induction of Labor - Comparison Propess With Prostaglandin E2 Vaginal Gel and Balloon Catheter Recruiting
Castor Oil Ingestion and Balloon Catheter for Labor Induction in Multiparous Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06990217 on ClinicalTrials.gov ↗ ← All trials in Israel